Cytokinetics presents data showing potential benefits of omecamtiv mecarbil in heart failure patients

From GlobeNewswire: 2024-11-16 09:00:00

Cytokinetics, Incorporated presented new data from post-hoc analyses of the GALACTIC-HF trial at the American Heart Association Scientific Sessions 2024, showing potential benefits of omecamtiv mecarbil in high-risk heart failure patients. Treatment with omecamtiv mecarbil reduced the risk of the primary endpoint in patients with severe heart failure regardless of age. A separate analysis revealed that ventricular arrhythmias were associated with adverse outcomes, but treatment with omecamtiv mecarbil reduced the risk of ventricular arrhythmias in patients with severely reduced ejection fraction. Omecamtiv mecarbil is an investigational cardiac myosin activator designed to improve heart function in heart failure patients.



Read more at GlobeNewswire: Cytokinetics Presents Additional Data From GALACTIC-HF at